Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08YWY
|
|||
| Former ID |
DNCL001681
|
|||
| Drug Name |
SCH-900117
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 1 | [1] | |
| Company |
Merck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-17 (IL17) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Inflammatory bowel disease (IBD) | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | |||
| Pathway Interaction Database | IL27-mediated signaling events | |||
| IL23-mediated signaling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| Allograft Rejection | ||||
| IL17 signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029914) | |||
| REF 2 | Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.